Adverum Biotechnologies, Inc. (ADVM) Dividend History

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing treatments for serious ophthalmic diseases. The company's approach involves using gene therapy to address unmet medical needs, aiming to provide long-term solutions for conditions such as wet age-related macular degeneration and diabetic macular edema. Founded in 2014, Adverum emphasizes innovation in its pursuit to restore or preserve vision through its proprietary delivery platforms.

100 Cardinal Way, Redwood City, CA, 94063
Phone: (650) 649-1004
Website: https://www.adverum.com

Dividend History

Adverum Biotechnologies, Inc. currently does not pay dividends

Company News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

Adverum Biotechnologies, Inc. disclosed non-cash errors in its financial statements, leading to a restatement of its financial results for 2022 and 2023. This news caused the company's stock price to drop by 12.36%.

GlobeNewswire Inc.
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

GlobeNewswire Inc.

Featured Companies: BIIB FDMT JNJ MGTX PASG RARE RCKT RGNX SRPT TNYA
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies has initiated the Phase 3 ARTEMIS trial to evaluate the efficacy and safety of its gene therapy candidate Ixo-vec for the treatment of wet age-related macular degeneration (AMD). The trial will compare Ixo-vec to the standard of care, aflibercept, in both treatment-naïve and previously treated patients.

GlobeNewswire Inc.
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Adverum Biotechnologies, a clinical-stage company focused on gene therapy for ocular diseases, announced that it will present at the Cowen 45th Annual Healthcare Life Sciences Conference on March 4, 2025.

GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The gene therapy market is experiencing significant growth, with over 180 companies actively developing more than 200 gene therapies. This dynamic landscape highlights the increasing investment and innovation in the sector, promising new treatment options for various diseases.

GlobeNewswire Inc.

Featured Companies: ALLO KYTX RARE RCKT

Dividend data last updated 06/06/2025 23:28:31 UTC